Cardiotoxicity of trastuzumab in clinical practice [26]

New England Journal of Medicine

Volumn 357, Issue 1, 2007, Pages 94-95

  McArthur, Heather L ^a   Chia, Stephen ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG WITHDRAWAL; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 34347389664     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070065     Document Type: Letter

References (5)

1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
4. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
5. McArthur HL, Barnett J, Chia S. A population-based study of adjuvant trastuzumab-mediated cardiotoxicity among early stage HER2+ breast cancer patients. Breast Cancer Res Treat 2006;100:Suppl 1:S113. abstract.